Top

Published in:

01-02-2011 | Drug and Profile Report

Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura

Published in: Drugs & Therapy Perspectives | Issue 2/2011

Excerpt

Oral eltrombopag is indicated to manage chronic immune (idiopathic) thrombocytopenic purpura in adults who have had an insufficient response to other treatments. In robust trials in this patient population, eltrombopag increased platelet count, reduced the risk of bleeding and was generally well tolerated …

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12; 113(11): 2386–93PubMedCrossRef

Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68(7): 901–12PubMedCrossRef

Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007 Oct; 44(4 Suppl. 5): S35–45PubMedCrossRef

Revolade (eltrombopag film-coated tablets): summary of product information. London: European Medicines Agency, 2010

Promacta® (eltrombopag): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009

Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424–30PubMedCrossRef

Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Feb 21; 373(9664): 641–8PubMedCrossRef

Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 3431]. Blood 2008; 112(11): 1176

Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. Epub 2010 Aug 23

10.

Saleh MN, Bussel JB, Cheng G, et al. Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study [abstract no. 682]. Blood 2009; 114(12): 1326

11.

Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 Nov 29; 357(22): 2237–47PubMedCrossRef

12.

Bussel JB, McHutchison J, Provan D, et al. Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies [abstract no. 1299]. Blood 2007; 110(11): 391a

13.

Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009; 69(5): 567–76PubMedCrossRef

Title: Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura
Publication date: 01-02-2011
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 2/2011
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/11202360-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

Manage incontinence-associated dermatitis effectively using optimal prevention and treatment regimens

Dapoxetine: a guide to its use in premature ejaculation

Most psychoactive therapies have the potential to cause ocular adverse events

News from the 39th European Symposium on Clinical Pharmacy; 21–23 October 2010; Lyon

First reports of serious adverse drug reactions in recent weeks

Tumour necrosis factor-α inhibitors have a growing role in managing late-onset ankylosing spondylitis and spondylarthritis